UNSPSC 51262603: Napamezole

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GK4C2D295B, chemically known as 2-((3,4-dihydro-2-naphthyl)methyl)-2-imidazoline but generally known as napamezole, which bears US NIH Compound Identifier 124655. European Medicines Agency schedules Napamezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09153MIG.

UNSPSC 51262603 Napamezole, a Commodity code, covers pharmaceutical products and chemical agents procured by state and local public health and emergency-management bodies. The recent solicitation activity under this code reflects procurement of naloxone and drug deactivation systems — medications and equipment supporting overdose response and controlled-substance management rather than napamezole itself. Issuing bodies soliciting under the code include county health departments and public-health districts managing community health initiatives and emergency preparedness.

Seminole County, Florida posted an IFB (Invitation for Bid) on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The response deadline was July 26, 2023. The contract carries a two-year initial term with a one-year renewal option and requires vendors to meet E-Verify compliance, drug-free workplace certification, and insurance coverage in commercial general liability and workers' compensation. Pricing is on a fixed-fee basis with shipping and delivery costs included in vendor proposals. The procurement was potentially FEMA-funded, introducing federal environmental compliance requirements and audit provisions. Geographic activity is limited to Florida in the recent record; no additional state or local opportunities under this code are documented in the source.